Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

MSD in the Philippines’ “Di Mo DeCERV!” campaign has been awarded Bronze in the Advocacy category at this year’s ICE Awards, ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...